Remote Controlled CARs: Towards a safer therapy for Leukemia

Cancer Immunology Research

Volumn 4, Issue 8, 2016, Pages 643-

  June, Carl H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; DOXYCYCLINE; HYBRID PROTEIN; TETRACYCLINE; LYMPHOCYTE ANTIGEN RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CELL ENGINEERING; CELL THERAPY; CLINICAL TRIAL (TOPIC); GENETIC ENGINEERING; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; LEUKEMIA; NONHUMAN; SYNTHETIC BIOLOGY; T LYMPHOCYTE; ADOPTIVE IMMUNOTHERAPY;

ANTIGENS, CD19; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, CHIMERIC ANTIGEN;

EID: 84985942548     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-16-0132     Document Type: Article

References (4)

1. Bhoj VG, Arhontoulis D, Wertheim G, Capobianchi J, Callahan CA, Ellebrecht CT, et al. Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T cell therapy. Blood 2016 May 10 [Epub ahead of print].
2. Berger C, Flowers ME, Warren EH, Riddell SR. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 2006;107:2294-302.
3. Rodgers DT, Mazagova M, Hampton EN, Cao Y, Ramadoss NS, Hardy IR, et al. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc Natl Acad Sci U S A 2016;113: E459-68.
4. Wu CY, Roybal KT, Puchner EM, Onuffer J, Lim WA. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science 2015;350:aab4077.